{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:54:36Z","timestamp":1761238476384},"reference-count":39,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T08:23:09Z","timestamp":1515745389000},"page":"471-477","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Timing of P2Y 12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?"],"prefix":"10.1016","volume":"60","author":[{"given":"Harsh","family":"Golwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2018.01.001_bb0005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0010","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","article-title":"Antiplatelet and anticoagulation therapy for acute coronary syndromes","volume":"114","author":"Bhatt","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2018.01.001_bb0020","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/CIR.0000000000000134","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.001_bb0025","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0035","first-page":"13","article-title":"Pretreatment with antiplatelet agents in the setting of percutaneous coronary intervention: when and which drugs?","volume":"6","author":"Capodanno","year":"2017","journal-title":"Interv Cardiol Clin"},{"key":"10.1016\/j.pcad.2018.01.001_bb0040","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.114.011319","article-title":"Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified","volume":"130","author":"Valgimigli","year":"2014","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.1016\/j.pcad.2018.01.001_bb0045","first-page":"25","article-title":"Pharmacokinetics of clopidogrel","volume":"25","author":"Caplain","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"suppl 2","key":"10.1016\/j.pcad.2018.01.001_bb0050","first-page":"29","article-title":"Pharmacokinetic profile of 14C-labeled clopidogrel","volume":"25","author":"Lins","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pcad.2018.01.001_bb0055","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0060","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.001_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0080","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ahj.2005.01.044","article-title":"Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"150","author":"Lewis","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0085","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.001_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2048872614520752","article-title":"Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction","volume":"3","author":"de Waha","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.pcad.2018.01.001_bb0095","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0100","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1016\/j.ijcard.2013.07.012","article-title":"Comparison of pre-hospital 600\u202fmg or 900\u202fmg vs. peri-interventional 300\u202fmg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load & Go randomized trial","volume":"168","author":"Ducci","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00392-011-0393-1","article-title":"Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial","volume":"101","author":"Zeymer","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0110","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.001_bb0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2016.11.226","article-title":"Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy","volume":"229","author":"Nairooz","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0120","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.001_bb0125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0130","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10928-008-9103-7","article-title":"Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"35","author":"Ernest","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.pcad.2018.01.001_bb0140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0150","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0155","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.001_bb0160","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pcad.2018.01.001_bb0175","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0180","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0185","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.001_bb0190","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.001_bb0195","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T18:52:55Z","timestamp":1535136775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062018300185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0033062018300185"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}